MEDIA ADVISORY - The SQDC to Extend the Opening Hours of Some Stores Français
Date: Friday, July 4, 2025
Time: 9:30 a.m.
Address: 84, rue Saint-Paul Est, Montréal
Company representatives at the event:
Suzanne Bergeron, President and Chief Executive Officer;
Alexander Bove, Director, Real Estate;
Jean-François Dulac-Lemelin, Senior Vice-President, Customer Experience;
Théogène Morin, Regional Director;
Mario Quattrociocche, Manager, Vieux-Montréal store; and
Alban Troja, Director, Evolution and Performance, Customer Experience.
Please note that interviews will be possible in French and English, microphone stands may be useful (no audio mult box) and parking is difficult in the area.
About the Société québécoise du cannabis (SQDC)
The SQDC is a government corporation mandated to distribute and sell cannabis in Québec with a focus on protecting customers' health and safety. The company is committed to offering quality products and informing and advising consumers on how to minimize the health impacts of cannabis. The goal is to shrink the illegal cannabis market in Québec. The declared dividend equal to the company's net income is transferred to the Fonds de lutte contre les dépendances, a fund managed by the Ministère des Finances du Québec, and reinvested primarily in cannabis-related education, prevention efforts and research. For more information, visit SQDC.ca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that Novotech has been awarded the 2025 Global Company of the Year Award in the biotech contract research organization (CRO) industry for its outstanding achievements in clinical trial innovation, strategic execution, and client-centric delivery. This recognition highlights Novotech's leadership in enabling biotech and small to mid-sized pharma companies to accelerate therapeutic development globally through flexible, high-touch, and technologically advanced clinical trial services. The company stands apart in the global CRO landscape with its strategic emphasis on serving biotech clients, offering tailored clinical trial solutions across all phases of development. The company operates in more than 30 locations and has cultivated deep local insights across key clinical trial hubs, including Australia, South Korea, India, China, and the United States. Its ability to combine global standards with regional excellence makes Novotech a trusted partner for biotech sponsors worldwide. "Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for biotech and small to midsize pharma, Novotech leverages deep therapeutic expertise and regional agility to deliver speed, flexibility, and transformative impact in clinical trials," said Unmesh Lal, vice president, healthcare & life sciences at Frost & Sullivan. With nearly three decades of experience, Novotech has built a robust reputation for delivering high-quality clinical trials at speed. Its integrated service model encompasses regulatory consulting, clinical operations, biometrics, data management, and medical writing, allowing clients to streamline their development pipelines from early phase to post-marketing studies. Through a powerful combination of local knowledge, scientific expertise, and digital capabilities, Novotech continues to enhance trial efficiency, patient recruitment, and regulatory outcomes. Novotech's dedication to advancing clinical research is further reflected in its strategic acquisitions and partnerships. The company's expansions into the United States and Europe marked a significant milestone in building a globally unified platform while preserving its excellence in APAC operations. Novotech's sustained growth trajectory is driven by its deep alignment with sponsors' evolving needs and its commitment to scientific excellence and operational agility. "We're honored by Frost & Sullivan's recognition, which highlights Novotech's strategic focus on delivering regional expertise through a global model to support biotech and mid-size pharma sponsors. It also reflects the strength of our teams in driving operational, scientific, and client delivery excellence worldwide," said Dr. John Moller, chief executive officer, Novotech Novotech's unwavering commitment to client experience strengthens its position in the market. By streamlining service delivery, enabling real-time trial visibility through advanced digital systems, and maintaining continuity across project teams, the company delivers exceptional client satisfaction. Its regionalized, partner-led delivery model and localized expertise ensure regulatory compliance and cultural alignment—key factors that drive trial success in various markets. Frost & Sullivan commends Novotech for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and client-first culture are shaping the future of biotech clinical trials and driving tangible outcomes that matter to patients and sponsors. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, client satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, client service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: Tarini Singh E: [email protected] About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
Winnipeg Free Press
5 hours ago
- Winnipeg Free Press
Manitoba urged to earmark 25 per cent of ad budget on local journalism
Manitoba has been advised to follow Ontario's lead by dedicating 25 per cent of its advertising budget to local publications, to help fund journalism since digital giants have swiped much of their revenue. 'This made an immediate and meaningful difference to many news titles (in Ontario),' Paul Deegan, president and CEO of News Media Canada, told an all-party committee of the legislature in Winnipeg Wednesday. Last year, Ontario Premier Doug Ford directed his government to spend 25 per cent of its advertising budget on local publications to bolster community journalism. BROOK JONES / FREE PRESS Free Press vice-president Christian Panson told the committee online platforms don't invest in Manitoba. 'We do.' 'For generations — all the way back to the founding of the Halifax Gazette in 1752 — government advertising had been an important source of revenue for news businesses. In recent years, this has waned considerably… Where did the money go? Largely to American tech giants like Google, Facebook/Instagram, Snapchat, Apple, and X (Twitter),' said Deegan, who travelled to Winnipeg from Toronto to appear in person on behalf of the national association of print and digital news media from each province and territory. The provincial government and its Crown corporations — Manitoba Hydro, Manitoba Public Insurance, Manitoba Liquor and Lotteries and Efficiency Manitoba — spend money to advertise public information campaigns, public hearings, health advisories and consumer programs, among other things. On Wednesday, 18 presenters spoke at three sessions. Christian Panson, vice-president of digital and technology at the Free Press, and Greg Vandermeulen, editor of the Steinbach Carillon, were among those who lobbied for dedicated funding. Panson recommended the provincial government redirect advertising spending from foreign platforms to local media outlets. 'These mega news platforms do not invest in Manitoba. We do,' Panson told the panel. He called for a tax credit to be issued to local businesses that advertise with qualified Manitoba media companies. Deegan said Quebec has instituted such a tax credit. 'It's probably the most efficient thing you can do,' he said. Panson advised that a program should be created to fund the hiring of journalists to cover communities that are underserved. 'Whether these are linguistics, linguistic, cultural or geographic news deserts, these communities deserve to have their stories told,' he said. The committee was established to consult with Manitobans about rural, northern and cultural media such as French, Filipino, Punjabi and Chinese language publications. New Democrat MLA Robert Loiselle chairs the committee that includes three other government MLAs — Diljeet Brar, Jennifer Chen and Eric Redhead — and three Progressive Conservative MLAs: Greg Nesbitt, Richard Perchotte and Konrad Narth. Deegan said there are 31 community newspapers in Manitoba, which is a significant drop from 48 publications just seven years ago. He said the government would benefit by advertising in community and ethnic newspapers because they more effectively reach specific audiences that trust their local news source. Greg Vandermeulen, who has been the editor of the Steinbach Carillon since 2019, detailed the impact of its reporting in southeast Manitoba. The newspaper, which was founded in 1946, covers more than a dozen municipalities and is the largest rural weekly in the province. 'We're a safe place to access information in a sea of misinformation,' Vandermeulen said. 'Our impact is noticed.' Vandermeulen says he's not pessimistic about the future of local media and with a little bit of help from the province, journalism in Manitoba can be sustained. A government spokesperson told the Free Press the majority of its advertising is spent in local markets. In the fiscal year that ended March 31, 2025, 77 per cent of the total budget for advertising, including from Crown corporations, was spent on local print, radio, television, billboards, and transit ads, while 23 per cent was spent on digital and social media ads. Following the presentations, Loiselle called the requests fair. 'I think the whole question of how we can maybe redirect some ad monies to better support local media is a great way of advancing forward… If they can do it in Quebec, if they can do it in Ontario, then maybe we might be able to do it in little old Manitoba,' he said. Committing 25 per cent of the ad budget to local publications is a good starting point, the MLA added. The committee is due to issue its report by the end of October. Weekday Mornings A quick glance at the news for the upcoming day. The hearing was the first consultation after the meeting scheduled for Gimli on June 26 was cancelled because no one had registered. So many people signed up to speak Wednesday in Winnipeg that the government added another session during the day. Public hearings are planned for Brandon on July 7, and Winkler on July 11. A virtual online session is being held for Thompson and northern Manitoba on July 8. In 2019, the federal government instituted a refundable tax credit on salaries or wages paid to eligible newsroom employees, and offered a 15 per cent non-refundable personal income tax credit for qualifying digital news subscriptions. Nicole BuffieMultimedia producer Nicole Buffie is a multimedia producer who reports for the Free Press city desk. Born and bred in Winnipeg, Nicole graduated from Red River College's Creative Communications program in 2020 and worked as a reporter throughout Manitoba before joining the Free Press newsroom in 2023. Read more about Nicole. Every piece of reporting Nicole produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Cision Canada
5 hours ago
- Cision Canada
World-Leading Breakthrough! Risen Energy's HJT Modules Hit Average 740Wp Mass Production with Record 26.61% Cell Efficiency
NINGBO, China, July 2, 2025 /CNW/ -- A milestone in global heterojunction (HJT) photovoltaic technology! Risen Energy Co., Ltd. (Stock Code: 300118) today announced its self-developed Hyper-ion HJT modules have achieved a groundbreaking 740Wp average mass-production power, setting a new industry efficiency benchmark. With certified cell conversion efficiency of 26.61%, this innovation demonstrates immediate R&D-to-production integration. This breakthrough cements Risen Energy's leadership in high-efficiency PV industrialization. Core Innovations: Patent-Protected Tech & Cost-Performance Revolution Leveraging National Key Research and Developement Program, Risen Energy's proprietary technologies deliver structural optimization and drastic cost reduction while maintaining peak efficiency: Metallization Upgrade: Silver consumption slashed to 5mg/W (↓37.5% vs. TOPCon), driving non-silicon cost reduction via stencil printing. Low CTM Loss Encapsulation: Module CTM (Cell-To-Module) loss minimized to 1.8% with cell breakage-rates under 0.03%, enabling high-yield manufacturing. Dual Advantages: High Energy Yield & Ultra-Low Carbon The 740W Hyper-ion module's -0.24%/°C temperature coefficient and 90% bifaciality delivered 4.09% higher power output than TOPCon at SGS Saudi Arabia's test site. Peak monthly gains hit 6.04% in August, proving its "higher heat, higher yield" reliability. Per 100MW project, this translates to: +3 million kWh annual power generation 2,880 tons CO₂ reduction Carbon footprint as low as 376.5kg eq CO₂/kWc Global Market Momentum As the prime solution for utility-scale, commercial/industrial, and high-temperature projects, Risen Hyper-ion Pro series HJT modules dominate: 9GW+ 2025 HJT-specific tenders in China (led by state-owned giants like China Green Dev./CGN etc.) Expansion to 50+ countries across Middle East/Southeast Asia 6%+ verified energy gain in Saudi/UAE high-irradiation regions, slashing LCOE. Vision from Leadership Dr. Yang Pochuan, Dean of Risen Global PV Research Institute: "We're targeting >27% cell efficiency and 790W+ monocrystalline modules within 3 years. Our perovskite tandem tech will enable 850Wp+ mass production by 2028, advancing the world's net-zero transition with 'China Solutions'. SOURCE Risen Energy Co., Ltd
